Evidence map›Paper›PMID 34429257›Full record

ReviewJournal of infection and public health2021

An overview of SARS-COV-2 epidemiology, mutant variants, vaccines, and management strategies.

Tahmeena Farooqi, Jonaid Ahmad Malik, Almas Hanif Mulla, Turki Al Hagbani, Khaled Almansour, Mohammed Abrar Ubaid, Saleh Alghamdi, Sirajudheen Anwar

Open access · goldAbstract readReview
In one paragraph

Review in Journal of infection and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 49 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Retinol Depletion in COVID-19.Clinical nutrition open science · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Tahmeena FarooqiDepartment of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, India.
Jonaid Ahmad MalikDepartment of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Guwahati, India; Department of Biomedical Engineering, Indian Institute of Technology (IIT), Ropar, Punjab, India.
Almas Hanif MullaDepartment of Pharmacology, Goa College of Pharmacy, Goa, India.
Turki Al HagbaniDepartment of Pharmaceutics, College of Pharmacy, University of Hail, Hail, Saudi Arabia.
Khaled AlmansourDepartment of Pharmaceutics, College of Pharmacy, University of Hail, Hail, Saudi Arabia.
Mohammed Abrar UbaidDepartment of Pharmaceutics, JSS College of Pharmacy, Ooty, Tamil Nadu, India.
Saleh AlghamdiDepartment of Clinical Pharmacy, Faculty of Clinical Pharmacy, Albaha University, Albaha, Saudi Arabia.
Sirajudheen AnwarDepartment of Pharmacology and Toxicology, College of Pharmacy, University of Hail, Hail, Saudi Arabia. Electronic address: si.anwar@uoh.edu.sa.
University of Ha'il · SAAl Baha University · SAIndian Institute of Technology Ropar · INJSS Academy of Higher Education and Research · INNational Institute of Pharmaceutical Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOver the last two decades, humanity has observed the extraordinary anomaly caused by novel, weird coronavirus strains, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). As the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus has made its entry into the world, it has dramatically affected life in every domain by continuously producing new variants. The vaccine development is an ongoing process, although some vaccines got marketed. The big challenge is now whether the vaccine candidates can provide long-lasting protection or prevention against mutant variants.

methodsThe information was gathered from various journals, electronic searches via Internet-based information such as PubMed, Google Scholar, Science Direct, online electronic journals, WHO landscape, world meters, WHO website, and News.

resultsThis review will present and discuss some coronavirus disease 19 (COVID-19) related aspects including: the pathophysiology, epidemiology, mutant variants vaccine candidates, vaccine efficacy, and management strategies. Due to the high death rate, continuous spread, an inadequate workforce, lack of required therapeutics, and incomplete understanding of the viral strain, it becomes crucial to build the knowledge of its biological characteristics and make available the rapid diagnostic and vital therapeutic machinery for the combat and management of an infection.

conclusionThe data summarizes current research on the COVID 19 infection and therapeutic interventions, which will direct future decision-making on the effort-worthy phases of the COVID 19 and the development of critical therapeutics. The only possible solution is the vaccine development targeting against all variant strains to halt its progress; the identified theoretical and practical knowledge can eliminate the gaps to improve a better understanding of the novel coronavirus structure and its design of a vaccine. In addition, to that the long-lasting protection is another challenging objective that need to be looked into.

Indexed as

COVID-19VaccinesCOVID-19 VaccinesHumansSARS-CoV-2COVID-19 VaccinesVaccinesEpidemiologySARS-COV-2Vaccine candidatesVariant strainsWHO landscape

Identifiers

PMID34429257
PMCPMC8366110
OpenAlexW3193616127

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.